Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Anne Knisely(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Wei Lü(The University of Texas MD Anderson Cancer Center), Khaja Khan(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Idania Carolina Lubo Julio(The University of Texas MD Anderson Cancer Center), Lorena I. Gomez-Bolanos(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Minetta C. Liu(Mayo Clinic), Rachel N. Grisham(Memorial Sloan Kettering Cancer Center), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Khalida Wani(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Barrett C. Lawson(The University of Texas MD Anderson Cancer Center), Punashi Dutta(Natera (United States)), Adam C. ElNaggar(St. Jude Children's Research Hospital), Alejandra G. Serrano(The University of Texas MD Anderson Cancer Center), Graham L. Barlow(Dana-Farber Cancer Institute), Brenda Melendez(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Sharlene Velichko(Natera (United States)), Travis T. Sims(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Sean Barnes(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), David M. Boruta(Massachusetts General Hospital), Samantha K. Cheung(Natera (United States)), Helen Clark(The University of Texas MD Anderson Cancer Center), Manoj Chelvanambi(The University of Texas MD Anderson Cancer Center), Roni Nitecki Wilke(The University of Texas MD Anderson Cancer Center), Chih‐Chen Yeh(The University of Texas MD Anderson Cancer Center), Carly Bess Scalise(Medical University of South Carolina), Pedro T. Ramirez(Houston Methodist), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Lois M. Ramondetta(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Luisa M. Solis Soto(The University of Texas MD Anderson Cancer Center), Jeffrey How(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Jianfeng Chen(The University of Texas MD Anderson Cancer Center), Ou Shi(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Bharat Singh(The University of Texas MD Anderson Cancer Center), Bhavana Singh(The University of Texas MD Anderson Cancer Center), Gwyn Richardson(The University of Texas MD Anderson Cancer Center), Rossana N. Lazcano(The University of Texas MD Anderson Cancer Center), Yibo Dai(Peking University)
Cited by 10
Related Papers
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k